Optimal management of type 2 diabetes: The evidence

Diabetes, Obesity and Metabolism

Volumn 14, Issue 1 SUPPL. 1, 2012, Pages 3-8

  Colagiuri, S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Glycated haemoglobin; Treatment algorithm; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TOLBUTAMIDE;

CONGESTIVE HEART FAILURE; DIET; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FLUID RETENTION; FOLLOW UP; FRACTURE; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INTERMETHOD COMPARISON; KIDNEY DISEASE; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); MONOTHERAPY; MORBIDITY; MORTALITY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINOPATHY; REVIEW; RHINOPHARYNGITIS; RISK REDUCTION; SIDE EFFECT; SMOKING CESSATION; SYSTEMATIC REVIEW (TOPIC); URINARY TRACT INFECTION; WEIGHT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 82255194253     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01506.x     Document Type: Review

References (34)

1. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
2. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes-STENO 2. N Engl J Med 2008; 358: 580-591.
3. Colagiuri S, Dickinson S, Girgis S, Colagiuri R. National evidence based guideline for blood glucose control in type 2 diabetes. Diabetes Australia and the NHMRC 2009. Available from URL: (Accessed 15 August 2011).
4. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34: s19.
5. Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32(suppl. 1): 580-591.
6. IDF. Global guideline for type 2 diabetes. 2005. Available from URL: (Accessed 15 August 2011).
7. NICE. Type 2 diabetes blood glucose guideline. 2008 Available from URL: (Accessed 15 August 2011).
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
9. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
10. ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
11. Ismail-Beigi F, Craven T, Banerji MA et al. ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376: 419-430.
12. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
13. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
14. Hemmingsen B, Lund SS, Gluud C et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. The Cochrane Library.
15. Institute for Quality and Efficiency in Health Care. Benefit assessment of long-term blood glucose lowering to near-normal levels in patients with type 2 diabetes mellitus. 2011. Institute for Quality and Efficiency in Health Care Report No. A05-07.
16. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
17. Ma J, Yang W, Fang N, Zhu W, Wei M. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis. Nutr Metab Cardiovasc Dis 2009; 19: 596-603.
18. Montori VM, Fernandez-Balsells M. glycemic control in type 2 diabetes: time for an evidence-based about-face?. Ann Intern Med 2009; 150: 803-808.
19. Yudkin JS, Richter B, Gale EAM. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010; 53: 2079-2085.
20. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
21. Bennett WL, Maruthur NM, Singh S et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602-613.
22. Prospective Diabetes UK Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
23. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011; 13: 221-228.
24. Schramm TK, Gislason GH, Vaag A et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32: 1900-1908.
25. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 2: CD003639.
26. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-16.
27. Home PD, Pocock SJ, Beck-Nielsen H et al for the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.
28. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206.
29. Kahn SE, Haffner SM, Heise MA, ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
30. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
31. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta- analysis. JAMA 2007; 298: 1189-1195.
32. Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive (PROspectivepioglitAzone Clinical Trial in macrovascular Events): a randomized controlled trial. Lancet 2005; 366: 1279-1289.
33. Rosenstock J, Sugimoto D, Strange P, Stewart JA, SoltesRak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006; 29: 554-559.
34. Giugliano D, Maiorino MI, Bellastela G, Chidini P, Esposito K. Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review. Diab Res Clin Pract 2011; 92: 1-10.